Tonghua Dongbao's aspart insulin injection approved for Indonesia market

Tonghua Dongbao Pharmaceutical Co., Ltd. announced it received a drug registration certificate for its aspart insulin injection from Indonesia's Food and Drug Supervisory Agency. This certificate allows the company to market its EZ RAPID brand of aspart insulin injection in Indonesia. This product is a fast-acting insulin analogue, administered as a pre-filled injection pen for treating diabetes.

This approval expands Tonghua Dongbao's international product line and strengthens its brand image, especially within "Belt and Road" initiative countries. Indonesia, with a population of 281 million in 2024, is Southeast Asia's largest economy and a growing market for diabetes treatments. Data from the International Diabetes Federation (2024) indicates 20.4264 million people aged 20-79 in Indonesia have diabetes, with a prevalence rate of 11.0%.

The market entry of Tonghua Dongbao's aspart insulin injection is expected to offer more treatment options for local diabetes patients and help address the substantial treatment gap in Indonesia, where 73.2% of diabetic patients remain undiagnosed. While preliminary production preparations have been made, actual sales performance will depend on market demand, policy changes, and competition.